Bladder cancer is the tenth most common cancer type worldwide. Urothelial carcinoma is the
most common type of bladder cancer and accounts for 90% of bladder cancer cases in the …

Context This review focuses on risk assessment and prediction tools for bladder cancer
(BCa). Objective To review the current knowledge on risk assessment and prediction tools to …

Although substantial progress has been made in cancer biology and treatment, clinical
outcomes of bladder carcinoma (BC) patients are still not satisfactory. The tumor …

We sought to define whether there are intrinsic molecular subtypes of high-grade bladder
cancer. Consensus clustering performed on gene expression data from a meta-dataset of …

Immunotherapies targeting the PD-1/PD-L1 axis are now a mainstay in the clinical
management of multiple cancer types, however, many tumors still fail to respond. CCL2 is …

Long noncoding RNAs (lncRNAs) have been associated with cancer immunity regulation
and the tumor microenvironment (TME). However, functions of lncRNAs of tumor-infiltrating …

Muscle-invasive bladder carcinoma (MIBC) constitutes a heterogeneous group of tumors
with a poor outcome. Molecular stratification of MIBC may identify clinically relevant tumor …

Muscle-invasive urothelial cancer (MUC), characterized by high aggressiveness and
significant heterogeneity, is currently lacking highly precise individualized treatment options …

The prognosis and treatment of bladder cancer have improved little in the past 20 years.
Bladder cancer remains a debilitating and often fatal disease, and is among the most costly …

Background The systemic immune-inflammation index (SII) has been used as a prognostic
marker for several cancer types, but there is no in-depth study in bladder cancer. This study …